MMP9 and chronic kidney disease: For example, inhibiting the methylation of Sod2 and Mmp9 has shown some success in reducing the symptoms of diabetic retinopathy.[48] Apabetalone, an oral bromodomain and extraterminal (BET) inhibitor, exhibits both anti‐inflammatory properties and the ability to reduce alkaline phosphatase levels in people with a probability of type 2 DM‐associated cardiovascular and chronic kidney disease.[49]